Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.77 |
| ▸ | NEK2 | P51955 | 4/20 | 0.77 |
| ▸ | CSF1R | P07333 | 3/20 | 0.77 |
| ▸ | KDR | P35968 | 3/20 | 0.77 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.77 |
| ▸ | STK3 | Q13188 | 3/20 | 0.77 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.77 |
| ▸ | BRSK1 | Q8TDC3 | 3/20 | 0.77 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.77 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.77 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.77 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.77 |
| ▸ | PIM1 | P11309 | 2/20 | 0.77 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.77 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.77 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.77 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.77 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734903 | 0.93 | PLK1 (0.77) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3742272 | 0.90 | PLK1 (0.72) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3933141 | 0.89 | PLK1 (0.78) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3749144 | 0.89 | PLK1 (0.78) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3731227 | 0.89 | PLK1 (0.73) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3749178 | 0.88 | PLK1 (0.64) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3742582 | 0.88 | PLK1 (0.68) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3736522 | 0.88 | PLK1 (0.80) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3734876 | 0.87 | NEK2 (0.68) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL4551324 | 0.87 | PLK1 (1.00) | PLK1NEK2CSF1RKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2017277-A1 | Thiophene-imidazopyridines | 4SC AG (DE) | 2009-01-21 | — | — | EP | claimed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| US-20160158186-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2016-06-09 | — | — | US | disclosed |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-8273890-B2 | Thiophene-imidazopyridines | 4SC AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| EP-2017277-A1 | Thiophene-imidazopyridines | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PLK1 2427/4885NEK2 2269/4885CSF1R 3750/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PLK1 2427/4885NEK2 2269/4885CSF1R 3750/4885 |
| US-20160158186-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR | DDOST, DAD1, PHGDH | PLK1 773/4885NEK2 2741/4885CSF1R 2391/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | PLK1 2427/4885NEK2 2269/4885CSF1R 3750/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PLK1 61/4885NEK2 576/4885CSF1R 3158/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | PLK1 346/4885NEK2 1643/4885CSF1R 3677/4885 |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PLK1 2427/4885NEK2 2269/4885CSF1R 3750/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | PLK1 514/4885NEK2 1824/4885CSF1R 3349/4885 |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | PIKFYVE, PIP4K2B, PIP5K1B | PLK1 642/4885NEK2 2328/4885CSF1R 2699/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | PLK1 2427/4885NEK2 2269/4885CSF1R 3750/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | PLK1 773/4885NEK2 2741/4885CSF1R 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.